港股異動丨多家機構集體唱好,康方生物盤中再度升超7%
康方生物(9926.HK)盤中再度拉昇升超7%,現報58.15港元,總市值504億港元。日前,公司依沃西HARMONi-2重磅研究成果在WCLC發表。摩根大通發表研報指,康方生物自研依沃西單抗注射液(AK112)單藥在治療PD -L1表達陽性非小細胞肺癌(NSCLC)患者的三期臨牀試驗中表現較帕博利珠1L優勝,風險比為0.51,目前對該產品全球三期試驗中取得成功,以及在中國獲取更多市場份額變得更有信心。該行上調其目標價至68港元,重申康方生物為中國生物科技領域中的首選,評級“增持”。另外,建銀國際上調康方生物目標價至59港元,維持“跑贏大市”評級;交銀國際上調康方生物目標價至77港元,續列為行業重點推薦股份;里昂上調康方生物目標價至72.1港元,上調銷售額及純利預測;中銀國際上調康方生物目標價至72港元,重申“買入”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.